淀粉样蛋白和神经退行性变血浆生物标志物与共病的关联。
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.
机构信息
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Alzheimers Dement. 2022 Jun;18(6):1128-1140. doi: 10.1002/alz.12466. Epub 2021 Sep 27.
Abstract
INTRODUCTION
Blood-based biomarkers of amyloid pathology and neurodegeneration are entering clinical use. It is critical to understand what factors affect the levels of these markers.
METHODS
Plasma markers (Aβ42, Aβ40, NfL, T-tau, Aβ42/40 ratio) were measured on the Quanterix Simoa HD-1 analyzer for 996 Mayo Clinic Study of Aging (MCSA) participants, aged 51 to 95 years. All other data were collected during in-person MCSA visits or abstracted from the medical record.
RESULTS
Among cognitively unimpaired (CU) participants, all plasma markers correlated with age. Linear regression models revealed multiple relationships. For example, higher Charlson Comorbidity Index and chronic kidney disease were associated with higher levels of all biomarkers. Some relationships differed between mild cognitive impairment and dementia participants.
DISCUSSION
Multiple variables affect plasma biomarkers of amyloid pathology and neurodegeneration among CU in the general population. Incorporating this information is critical for accurate interpretation of the biomarker levels and for the development of reference ranges.
摘要
简介
血液淀粉样蛋白病理和神经退行性变的生物标志物正开始应用于临床。了解哪些因素会影响这些标志物的水平至关重要。
方法
对 996 名年龄在 51 至 95 岁的梅奥诊所老龄化研究（MCSA）参与者的血浆标志物（Aβ42、Aβ40、NfL、T-tau、Aβ42/40 比值）进行了 Quanterix Simoa HD-1 分析仪的检测。所有其他数据均在 MCSA 现场访问期间收集或从病历中提取。
结果
在认知正常（CU）参与者中，所有血浆标志物均与年龄相关。线性回归模型揭示了多种关系。例如，较高的 Charlson 合并症指数和慢性肾脏病与所有生物标志物水平升高相关。轻度认知障碍和痴呆症参与者之间的一些关系存在差异。
讨论
多种变量会影响一般人群中认知正常者的血液淀粉样蛋白病理和神经退行性变的血浆生物标志物。纳入这些信息对于准确解释生物标志物水平和建立参考范围至关重要。
相似文献
1
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.淀粉样蛋白和神经退行性变血浆生物标志物与共病的关联。
Alzheimers Dement. 2022 Jun;18(6):1128-1140. doi: 10.1002/alz.12466. Epub 2021 Sep 27.
2
Predicting amyloid PET and tau PET stages with plasma biomarkers.用血浆生物标志物预测淀粉样蛋白 PET 和 tau PET 分期。
Brain. 2023 May 2;146(5):2029-2044. doi: 10.1093/brain/awad042.
3
Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.脑脊液神经退行性变生物标志物与阿尔茨海默病和血管病理学标志物的相关性。
J Alzheimers Dis. 2023;92(3):887-898. doi: 10.3233/JAD-221015.
4
Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.血浆淀粉样蛋白、tau 蛋白和神经退行性变生物标志物与脑微出血的关系。
J Alzheimers Dis. 2022;87(4):1537-1547. doi: 10.3233/JAD-220158.
5
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.血浆 Aβ42/Aβ40、磷酸化 tau 和神经丝轻链对脑淀粉样变预测的种族影响。
Neurology. 2022 Jul 19;99(3):e245-e257. doi: 10.1212/WNL.0000000000200358. Epub 2022 Apr 21.
6
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.血浆神经丝轻链与阿尔茨海默病影像学生物标志物的阶段特异性关联。
Brain. 2020 Dec 1;143(12):3793-3804. doi: 10.1093/brain/awaa342.
7
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.阿尔茨海默病患者纵向血浆神经丝轻链与神经退行性变的关系。
JAMA Neurol. 2019 Jul 1;76(7):791-799. doi: 10.1001/jamaneurol.2019.0765.
8
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.利用血浆Aβ42/Aβ40和磷酸化tau蛋白组合检测早期阿尔茨海默病中的淀粉样蛋白阳性
Alzheimers Dement. 2022 Feb;18(2):283-293. doi: 10.1002/alz.12395. Epub 2021 Jun 20.
9
Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.阿尔茨海默病连续体中的血浆 Aβ42/40 比值、p-tau181、GFAP 和 NfL：AIBL 队列的横断面和纵向研究。
Alzheimers Dement. 2023 Apr;19(4):1117-1134. doi: 10.1002/alz.12724. Epub 2022 Jul 21.
10
Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.阿尔茨海默病血浆生物标志物与一个多种族队列认知功能和合并症的相关性。
Neurology. 2023 Oct 3;101(14):e1402-e1411. doi: 10.1212/WNL.0000000000207675. Epub 2023 Aug 14.
引用本文的文献
1
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab.在一项使用lecanemab的临床前阿尔茨海默病试验中，血浆p-tau217比率生物标志物合格率的种族和民族差异。
Alzheimers Dement (Amst). 2025 Aug 22;17(3):e70164. doi: 10.1002/dad2.70164. eCollection 2025 Jul-Sep.
2
Multimorbidity in dementia: Current perspectives and future challenges.痴呆症中的多重疾病：当前观点与未来挑战。
Alzheimers Dement. 2025 Aug;21(8):e70546. doi: 10.1002/alz.70546.
3
Standardized Procedures for Blood and Cerebrospinal Fluid Collection and Storage in Neurodegenerative Biomarker Research: A Comprehensive Review.神经退行性生物标志物研究中血液和脑脊液采集与储存的标准化程序：综述
Dement Neurocogn Disord. 2025 Jul;24(3):162-173. doi: 10.12779/dnd.2025.24.3.162. Epub 2025 Jul 17.
4
Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition: Beyond .对抗基因异质性以进行脑β淀粉样蛋白沉积易感性的多基因预测：超越……
Neurol Genet. 2025 Jul 21;11(4):e200266. doi: 10.1212/NXG.0000000000200266. eCollection 2025 Aug.
5
Factors related to blood-based biomarkers for neurodegenerative diseases and their intergenerational associations in the Young Finns Study: a cohort study.在芬兰青年研究中与神经退行性疾病血液生物标志物相关的因素及其代际关联：一项队列研究
Lancet Healthy Longev. 2025 Jun;6(6):100717. doi: 10.1016/j.lanhl.2025.100717.
6
Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease.肥胖对阿尔茨海默病血浆生物标志物及淀粉样蛋白PET轨迹的影响。
Alzheimers Dement (Amst). 2025 Jul 3;17(3):e70143. doi: 10.1002/dad2.70143. eCollection 2025 Jul-Sep.
7
Prospective evaluation of plasma pTau stability for the detection of Alzheimer's disease in a tertiary memory clinic.在三级记忆门诊对血浆磷酸化tau蛋白稳定性用于阿尔茨海默病检测的前瞻性评估。
Alzheimers Res Ther. 2025 Jul 5;17(1):150. doi: 10.1186/s13195-025-01779-7.
8
Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort.评估血浆p-tau217在基于社区的异质队列中检测淀粉样蛋白病理的作用。
Alzheimers Dement. 2025 Jul;21(7):e70426. doi: 10.1002/alz.70426.
9
Multimorbidity patterns and blood biomarkers of Alzheimer's disease in community-dwelling cognitively unimpaired older adults.社区居住的认知未受损老年人中阿尔茨海默病的共病模式和血液生物标志物
Alzheimers Dement. 2025 Jun;21(6):e70411. doi: 10.1002/alz.70411.
10
Kidney function is associated with plasma ATN biomarkers among Hispanics/Latinos: SOL-INCA and HCHS/SOL results.西班牙裔/拉丁裔人群的肾功能与血浆急性肾损伤生物标志物相关：SOL-INCA和HCHS/SOL研究结果
Alzheimers Res Ther. 2025 Jun 19;17(1):137. doi: 10.1186/s13195-025-01786-8.
本文引用的文献
1
Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults: A Registry-Based Study.老年人的肾功能、肾功能衰退与痴呆风险：一项基于登记处的研究
Neurology. 2021 Jun 14;96(24):e2956-e2965. doi: 10.1212/WNL.0000000000012113.
2
Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70.在英国出生队列中，对 70 岁人群进行基于人群的临床前期阿尔茨海默病血液筛查。
Brain. 2021 Mar 3;144(2):434-449. doi: 10.1093/brain/awaa403.
3
Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates.心房颤动中的血清神经丝轻链：临床、神经影像学及认知相关性
Brain Commun. 2020 Oct 6;2(2):fcaa166. doi: 10.1093/braincomms/fcaa166. eCollection 2020.
4
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.基于 ELISA 和 SIMOA 的血浆 Aβ 比值定量比较用于脑淀粉样血管病的早期检测。
Alzheimers Res Ther. 2020 Dec 5;12(1):162. doi: 10.1186/s13195-020-00728-w.
5
Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study.年龄和性别对有主观记忆主诉者的血浆 NFL 和 t-Tau 轨迹有影响：一项 3 年随访研究。
Alzheimers Res Ther. 2020 Nov 12;12(1):147. doi: 10.1186/s13195-020-00704-4.
6
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.阿尔茨海默病早期纵向血浆 p-tau217 增加。
Brain. 2020 Dec 5;143(11):3234-3241. doi: 10.1093/brain/awaa286.
7
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.血浆 tau 蛋白、神经丝轻链和淀粉样 β 水平与痴呆风险：一项基于人群的队列研究。
Brain. 2020 Apr 1;143(4):1220-1232. doi: 10.1093/brain/awaa054.
8
Serum neurofilament light levels in normal aging and their association with morphologic brain changes.血清神经丝轻链水平在正常衰老中的变化及其与形态学脑改变的关系。
Nat Commun. 2020 Feb 10;11(1):812. doi: 10.1038/s41467-020-14612-6.
9
Confounding effect of blood volume and body mass index on blood neurofilament light chain levels.血容量和体重指数对血液神经丝轻链水平的混杂影响。
Ann Clin Transl Neurol. 2020 Jan;7(1):139-143. doi: 10.1002/acn3.50972. Epub 2020 Jan 1.
10
Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers.考虑阿尔茨海默病相关生物流体生物标志物的测量和解释中的性别差异。
J Appl Lab Med. 2020 Jan 1;5(1):158-169. doi: 10.1373/jalm.2019.030023.
Zotero 插件